$GKOS News

BTIG Maintains Buy on Glaukos, Raises Price Target to $162

Glaukos (GKOS) Price Target Increased by 12.59% to 154.96

JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $140

Citigroup Maintains Buy on Glaukos, Raises Price Target to $140

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $138

Needham Maintains Buy on Glaukos, Raises Price Target to $136

BTIG Maintains Buy on Glaukos, Raises Price Target to $141

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos Corp (NYSE:GKOS) Shares Surge on Record Sales and Raised Guidance After Q1 Beat

Glaukos shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 sales guidance above estimates.

Glaukos Says CMS Assigns Permanent Healthcare Common Procedure Coding System J-Code For Epioxa HD / Epioxa For Treatment Of Keratoconus

Glaukos To Feature Its Technologies In Various Scientific Programming At ASCRS Annual Meeting

Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules

Glaukos Announces Commercial Availability Of Epioxa, First FDA Approved Incision Free Topical Drug Therapy For Keratoconus

Glaukos shares are trading higher after multiple analyst firms raised their respective price targets on the stock.

These Analysts Boost Their Forecasts On Glaukos Following Q4 Results

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $135

Needham Maintains Buy on Glaukos, Raises Price Target to $127

Expert Outlook: Glaukos Through The Eyes Of 10 Analysts

BTIG Reiterates Buy on Glaukos, Maintains $131 Price Target